Qualitative evaluation of meaningful change in Dravet syndrome as measured by the Vineland-3: Caregiver and clinician perspectives
- PMID: 40188607
- DOI: 10.1016/j.yebeh.2025.110381
Qualitative evaluation of meaningful change in Dravet syndrome as measured by the Vineland-3: Caregiver and clinician perspectives
Abstract
The Vineland Adaptive Behavior Scales, Third Edition (Vineland-3) is used to assess non-seizure outcomes in developmental and epileptic encephalopathies, including Dravet syndrome (DS); meaningful change thresholds (MCTs) have not been established. This qualitative study examined MCTs for the Vineland-3 and associated life impacts. Semi-structured interviews with 18 caregivers of children/adolescents with DS, including concept elicitation then completion and qualitative exploration of meaningful change for eight Vineland-3 subdomains considered most relevant to DS were conducted. Findings were used in clinical expert discussions. Caregivers spontaneously reported 35 signs/symptoms; most frequent were seizures (n = 16). Disruptive behavior, delays in adaptive behavior, and impaired communication were considered important to change with treatment. Raw score improvements ranging from 1 to 3 points (2 to 3 growth scale values) across subdomains were considered meaningful to ≥50 % of caregivers. These meaningful changes were associated with greater patient independence and safety. Caregivers ranked expressive and receptive communication as most important for improvement. Clinical experts' feedback regarding clinically meaningful changes aligned with caregivers' feedback. Clinical experts highlighted multiple factors for determining Vineland-3 MCTs in DS, including age, underlying intellectual and developmental ability, and presence of autism spectrum disorder. Overall, small changes on the Vineland-3 were considered meaningful to caregivers and clinical experts and were associated with important impacts for patients and families. This study provides novel insights supporting Vineland-3 MCT selection in DS, supporting the Vineland-3's use to explore non-seizure treatment-related benefit in clinical trial settings. Further evaluation of MCTs via in-trial interviews and quantitative anchor-based methods may be considered.
Keywords: Caregiver; Clinical expert; Dravet syndrome; Meaningful change thresholds; Qualitative interviews; Vineland Adaptive Behavior Scales, Third Edition.
Copyright © 2025 The Authors. Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: CC, KP, AD, and FW are employees of Stoke Therapeutics, Massachusetts, United States of America. MM, SW, AG and AM-S are employees of Adelphi Values and CH was an employee of Adelphi Values during the conduct of this research, a health outcomes agency contracted by Stoke Therapeutics to conduct the research. PV is an employee of CogState, the third party who conducted interviews with caregivers and who received funding from Stoke Therapeutics. JS and KK were clinical experts included on the panel and such received compensation for their role with the clinical expert meeting and follow-up activities.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical